Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-GEA: Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin in First-Line mGEA
NCT06628310Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Primary completion
- Oct 2030
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 11
01
Overview
Phase 2, randomised trial of telisotuzumab adizutecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Progression-Free Survival at 6 years and Objective Response Rate at 6 years. Started Dec 2024; status: active, not recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT06628310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06628310.